Thursday, June 11, 2026
Google search engine
Home Blog Page 7

Traces of rare purple dye mentioned in Bible passages found in ‘remarkable’ discovery

0

NEWYou can now listen to Fox News articles!

Archaeologists recently uncovered traces of a rare purple dye associated with biblical-era luxury in an unexpected place.

They found them at Roman infant burials sites in England.

The York graves date from the late third or early fourth century A.D. One infant was laid to rest alongside two adults in a stone coffin — while the other was buried in a lead coffin.

SINKHOLE IN HISTORIC CITY REVEALS MEDIEVAL HOSPITAL HIDING JUST BENEATH STREET LEVEL

Researchers recently analyzed the preserved remains and textiles in the burials. Using chemical testing, they found traces of Tyrian purple.

“The babies were wrapped in a fine textile of Tyrian purple embellished with gold thread — a cloth of the highest possible status and luxury known in the Roman world,” an April 30 statement from the University of York noted. 

Researcher analyzing cloth with purple dye

Archaeologists in England uncovered traces of rare Tyrian purple dye in Roman infant burials dating back centuries. (University of York)

The find “suggests the babies were from families of significant social standing,” officials said, adding that the purple cloth was “normally reserved for emperors and members of the aristocracy.”

The university said that “during the Roman period, the dye was a commodity valued at up to three times the price of gold.”

ANCIENT ESTATE TIED TO GROUP IN THE BIBLE UNEARTHED WITH ‘FASCINATING’ TREASURES IN ISRAEL

The dye, harvested by crushing the shells of murex mollusks, was mentioned in the Bible several times.

One biblical reference to purple textiles appears in Acts 16:14, which describes a female merchant.

“It’s one of only a handful of examples of the dye found in the U.K.”

In Mark 15:17, Jesus was dressed in purple cloth by his captors in order to humiliate him, since the color was associated with royalty.

ANCIENT ROMAN FORT YIELDS 2,000-YEAR-OLD FRUIT THAT SURVIVED THE CENTURIES, PLUS OTHER TREASURES

The verse says, “And they clothed him in a purple cloak; and after twisting some thorns into a crown, they put it on him.”

Officials said the textiles survived thanks to the Roman ritual of “pouring liquid gypsum over the clothed and shrouded bodies of the dead.”

Depiction of Roman York, birds' eye view of buildings

Archaeologists said Eboracum, founded by the Romans around 71 A.D., yielded one of Britain’s rare examples of Tyrian purple. (English Heritage/Heritage Images/Getty Images)

“The gypsum gradually hardened, protecting imprints and fragments of textiles, as well as the dyes and substances originally present in the fabrics,” the release added.

The discovery marks the “first time traces of the dye have been found on Roman textile remains in York,” officials said.

“It’s one of only a handful of examples of the dye found in the U.K.,” the release added.

CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER

Professor Maureen Carroll, a project director with University of York’s Department of Archaeology, called the discovery “remarkable.”

“For the first time we now have confirmation of the use of this costly dye in Roman York, indicating that the city’s wealthy inhabitants had access to expensive and exotic commodities from the other end of the empire,” said Carroll.

View of tourists outside York city walls

Roman infant graves discovered in York are shedding new light on the presence of wealthy families living in ancient Britain. (Germán Vogel via Getty Images)

The archaeologist added that the research “tells us a lot about the importance of children in Roman York and the willingness of the family to give their baby the best possible send-off in tragic circumstances.”

York, once known as Eboracum in Roman times, was founded around 71 A.D. as a military fortress.

CLICK HERE FOR MORE LIFESTYLE STORIES

It functioned as a provincial capital until the Romans effectively withdrew from Britain in the early fifth century.

Fox News Digital reached out to the University of York for comment.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The discovery comes around a year after experts released research about an ancient purple dye factory located in modern-day Israel.

Historians displaying ancient purple dye tools and a depiction of Justinian wearing purple robes

Historians recently unveiled findings about an ancient purple dye factory, highlighting the value of purple dye in ancient times — as seen on the robes of Justinian. (Maria Bukin/PLOS/Getty Images)

The site, Tel Shiqmona, “can unequivocally be identified as a specialized facility for large-scale and long-term production of the lucrative purple dye,” according to the study’s authors.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The site dates back as early as 1100 B.C., and researchers said the site had an “unparalleled” number of artifacts related to purple dye manufacturing.

Source

BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF

0

SYDNEY, June 1, 2026 /PRNewswire/ — Clean energy leader BLUETTI is unleashing massive EOFY deals during June 1–30, up to 44% off its diverse portable power stations and home backup systems. The world’s smallest 3kWh power station Elite 300, the best entry-level Elite 100 V2, and the versatile Apex 300 headline the shopping spree of the year, with exciting online activities unlocking additional discounts, gifts, and exclusive offers.

BLUETTI EOFY Sale is On
BLUETTI EOFY Sale is On

Must-Buy EOFY Power Station Deals

From weekend camping trips to reliable off-grid home backup, BLUETTI’s comprehensive energy solutions have every scenario covered. Most of them are now available at the lowest EOFY prices:

Elite 100 V2 (1,800W/1,024Wh): Now at $899 (was $1,299), this 11.5kg lightweight unit moves easily between homes and outdoors to run fridge freezers, microwaves, and e-bike chargers. Adding the Charger 1 completes a 560W car charging kit together for only $1,199 (was $1,699). With a 200W solar panel, the bundle is also marked down to $1,349(was $1,899).

Elite 300 (2,400W/3,014Wh): A 3kWh beast in a 2kWh size, for only $2,499(was $3,199). Eight useful outlets, with 12V/30A DC output, and multi-source charging make it well-suited for outdoor scenarios, caravans and home backup. The Charger 2 kit enables quick top-ups via solar and alternator inputs, which is reduced to $2,899(was $3,799), while the Sora 500 solar combo hits an all-time low of $3,499(was $4,898).

Apex 300 (3,840W/2,764.8Wh): Down to $2,999 (was $3,599), it evolves with needs using modular accessories, forming a 58kWh home storage or a 19.2kW solar setup.

More Savings From BLUETTI

Beyond direct markdowns, buyers can maximise their EOFY budgets by participating:

Buy More, Save More: Get $80 off orders over $1500, $135 off $2500, and $240 off $4,000.

Lucky Draws: Subscribe to win coupons, BLUETTI Bucks, or Lifestyle gifts.

Point Redemption: Redeem Bucks for cash-value discounts at checkout.

BLUETTI is also offering bulk purchase discounts, social media giveaways, and exclusive member-only deals throughout the EOFY sale.

From off-grid adventures to home backup, BLUETTIs EOFY Sale brings some of the years best deals on portable power solutions. Explore the deals before June 30 on BLUETTI’s website.

About BLUETTI

Founded in 2013, BLUETTI is a technology pioneer in clean energy, specialising in top-notch portable power stations, home backup batteries, and solar solutions. Driven by a mission to provide sustainable power to all, BLUETTI is trusted by over 3.5 million households across 140 countries.

Source

French Open delivers another shock Iga Swiatek goes down in straight sets to Marta Kostyuk

0

Iga Swiatek’s dream of a fifth French Open title has been shattered on her 25th birthday by an inspired Marta Kostyuk as the boilovers keep coming at Roland Garros.

A day after women’s champion Coco Gauff crashed out and hot on the heels of the exit of men’s giants Jannik Sinner and Novak Djokovic, third seed Swiatek was simply swept aside in her fourth-round clash 7-5, 6-1 by the Ukrainian on Court Philippe Chatrier.

Swiatek’s birthday celebrations quickly turned sour after she succumbed in a tight first set when she and Kostyuk twice traded breaks.

Know the news with the 7NEWS app: Download today Arrow

The 15th-seeded Kostyuk moved into overdrive in the second set once she’d saved three break points to move 2-1 ahead.

From that point, she lost just three more points, hitting a purple patch that left the Pole powerless with a host of searing winners – 25 in all over the one-hour 39-minute contest.

The victory left 23-year-old Kostyuk stunned as she’d never taken a set off Swiatek in their three previous meetings.

“I’m in shock,” she told the crowd.

“To beat such an unbelievable player who won four times here, I’d never taken a set off her; I still cannot believe it,.

“I think the most important thing I’ve been doing is really just trying to enjoy. I woke up this morning and I just thought about what an unbelievable day I have to live today to play on Chatrier against Iga.”

Source

Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders

0

SHANGHAI, May 31, 2026 /PRNewswire/ — The 28th Shanghai International Film Festival (SIFF) has officially unveiled the competition selections for the 2026 Golden Goblet Awards.

Held from June 12 to 21, the Festival received approximately 4,100 submissions from 125 countries and regions this year, setting a new historical record. According to the Festival, around 3,000 films met the eligibility requirements for competition, while 82% of the submitted entries are world or international premieres. The Festival also expanded its reach with first-time submissions from countries including Ghana and Mozambique.

Notably, all 12 films selected for the Golden Goblet Main Competition will make their world premieres in Shanghai. This marks the first time in the history of the Golden Goblet Awards that the Main Competition has achieved a 100% world-premiere lineup, underscoring Shanghai’s growing appeal as a launch platform for filmmakers from around the world.

The Golden Goblet Awards remain the centerpiece of SIFF’s international competition program, covering Main Competition, Asian New Talent, Documentary, Animation, and Short Film sections.


MAIN COMPETITION

ATLANTIC RHAPSODY
Director: ZHONG Kaifeng
(China)

HALIMA
Director: Yassine El Idrissi
(Morocco)

ILUMINADA
Director: Nicolás Rincón Gille
(Belgium)

LUIZA’S DESERT
Director: Alan Minas
(Brazil, United Kingdom)

MY OWN LAST SUPPER
Director: ismail BASBETH
(Indonesia)

NIGHT OF BLINDNESS
Director: Reis Çelik
(Turkey, Germany)

SEA SONS
Director: Daniil Merkulov
(Russia)

SECRET IN THE BOX
Director: Frankie Tam Kwong Yuen
(Chinese Mainland, Hong Kong China)

SUPERBUHEI
Director: Josef Brandl
(Germany)

THE GREAT SKULL
Director: LIU Xiaoyang
(China)

THE MISERABLE MOTHER
Director: Susanne Heinrich
(Germany, France)

THE PARKING SPOT
Director: Louis Godbout
(Canada)

ASIAN NEW TALENT

9 TEMPLES TO HEAVEN
Director: Sompot Chidgasornpongse
(Thailand)

ABOUT THE MOTHER
Director: Büşra Bülbül
(Turkey)

BOOMAH
Director: Zaid Abu Hamdan
(Jordan, Saudi Arabia)

CASSOWARY
Director: ZHANG Hanyi
(China)

DOG DAY EVENING
Director: Mak Tin Shu
(Chinese Mainland, Hong Kong China)

HER FIRST TASTE
Director: GONG Yiwen
(China)

HUNTER’S MOON
Director: Ridham Janve
(India, Germany)

NO GOOD IN SIGHT: A STORY
Director: Alibi Mukushev
(Kazakhstan)

NO HARD FEELINGS
Director: LIU Shichuan
(China)

SKYLARK
Director: Narghiza Dotieva
(Kyrgyzstan)

STRANGERS IN THE MOUNTAIN
Director: WAN Bo
(China)

THE BLIND GIRL AND AN ELEPHANT
Director: Ishtiyak Ahmad Zihad
(Bangladesh, Germany)

DOCUMENTARY

BENIGNO
Director: David Baute
(Spain)

NOTES UNHEARD
Director: GU Yun
(China)

RUINS
Director: Elena Chemerska
(North Macedonia, Croatia, Slovenia)

THE TIGER OF THE EAST
Director: Jorge Acevedo
(Chile)

WHEELS OF FORGOTTEN DREAMS
Directors: Milos Ljubomirovic, Danilo Lazovic
(Serbia, Bulgaria, Croatia)

ANIMATION

AMADEO AND THE HYPOTHETICAL NEW WORLD
Directors: Brenda Lígia, Edu Felistoque
(Brazil)

DANTE
Director: Linda Hambäck
(Sweden, Norway, Denmark)

GARUDA: DARE TO DREAM
Director: Ronny Gani
(Indonesia)

LUCY LOST
Director: Olivier Clert
(France)

WINNIPEG, SEEDS OF HOPE
Directors: Elio Guiroga, Beñat Beitia
(Spain, Chile, Argentina )

SHORT FILM (LIVE ACTION)

2000
Director: Renata Lučić
(Croatia)

CHICKEN LADY
Director: YUAN Shuqi
(China, USA)

ELSEWHERE
Director: LIN Tingxuan
(China, Thailand)

KILL, KOKESH, KILL!
Director: Jan Míka
(Czech Republic)

LAST TRAIN
Director: XU Weihao
(China)

LAZARE
Director: Claire Dietrich
(France)

SITTING BIRD
Director: Athena Han
(Canada)

THE DROUGHT
Director: Cristian Popa
(Romania)

THE MATCHMAKER
Director: Sophia Kuestenmacher
(Germany)

ZAZA GOGOGO
Director: CHEN Kedi
(China)

SHORT FILM (ANIMATED)

IF ONLY
Director: Ada Guvenir
(Belgium)

JULKA
Director: Valeria Cozzarini
(Slovenia, Italy)

SHOES
Director: Salvatore Centoducati
(Italy)

UNPLUG
Director: Comandante Bebé
(Spain)

WATER’S TIME SLICE
Director: HE Jiaxuan
(China)

Hong Kong actor Tony Leung Chiu-wai serves as President of the Main Competition Jury, while Singaporean filmmaker Anthony Chen chairs the Asian New Talent section. Documentary filmmaker Geeta Gandbhir heads the Documentary Jury, British animator Will Becher leads the Animation Jury, and Portuguese filmmaker João Salaviza serves as President of the Short Film Jury.

This year’s Festival will present more than 420 international films across over 1,500 screenings throughout Shanghai.

Source

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

0
  • Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
  • In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response. 

SHANGHAI, May 31, 2026 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, today announced the presentations of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. One study evaluated DZD6008, an investigational fourth-generation EGFR TKI, in pre-treated NSCLC patients with EGFR C797X mutations following progression on third-generation EGFR TKI treatment. The results were featured in an oral presentation. The other study reported results for golidocitinib, a JAK1-selective inhibitor, combined with an anti-PD-1 antibody as a first-line treatment for PD-L1-positive, advanced NSCLC without driver mutations.

DZD6008: A Fourth-Generation EGFR TKI Overcomes Resistance Following Third-Generation EGFR TKI Failure

The latest findings showed that DZD6008 demonstrated strong and durable anti-tumor activity in patients relapsed from third-generation EGFR TKI with a favorable safety profile.

  • The majority of patients (82.1%) had tumor shrinkage following DZD6008 treatment. Higher response rate is expected with longer treatment.
  • Tumor response is durable, with 6 months progression free survival (PFS) rates at 70.6% and 61.8%, respectively for 40 mg and 60 mg cohorts. The median duration of response (DoR) was not reached.
  • Excellent blood-brain barrier (BBB) penetration was observed, including strong intracranial anti-tumor activity among patients with baseline brain metastasis.
  • DZD6008 demonstrated a favorable safety profile with high selectivity for wild-type EGFR, resulting in minimal adverse effects.

Patients with EGFR-mutant NSCLC whose disease progresses on or after third-generation EGFR TKI treatment often acquire resistance mutations, among which EGFR C797X is one of the most frequently reported. DZD6008 is a fourth-generation EGFR TKI designed with full BBB penetration and high selectivity over wild-type EGFR. Preclinical and clinical data support its potent activities against single, double and triple EGFR mutations (L858R/19del, T790M, C797X).

Golidocitinib: A JAK1 Inhibitor Combined with Anti-PD-1 Demonstrates Durable Clinical Benefit

Among 47 enrolled treatment-naïve patients with advanced NSCLC, golidocitinib plus sintilimab following chemo-immunotherapy demonstrated encouraging and durable anti-tumor efficacy, particularly in those with high PD-L1 expression. Profound improvement of irAE was noticed.

Dr. Xiaolin Zhang, CEO of Dizal, said: “Main reasons for patients relapsed from 3rd generation EGFR TKI treatment include acquired resistance mutations and CNS metastasis. DZD6008 was designed to address these clinical issues. The data presented confirmed that DZD6008 met our design criteria and has the potential to provide an oral safe treatment option for these patients. We are very excited by the clinical data. We look forward to collaborating with investigators worldwide to accelerate its clinical development globally.”

About Golidocitinib (DZD4205)

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).

At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.

Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4).

About DZD6008

DZD6008 is a novel, highly selective, full-BBB penetrant EGFR TKI, designed as a potential treatment option for advanced EGFR mutation positive (EGFRm) NSCLC.

Non-small cell lung cancer is the leading cause of cancer death in the world. Epidermal growth factor receptor (EGFR) gene is one of the most common driver genes for NSCLC. Multiple agents can be used to treat patients with EGFR mutated NSCLC who develop resistance to EGFR tyrosine kinase inhibitors (TKIs), but the clinical outcome was not satisfactory. Brain metastases (BM) are a leading cause of death and disease progression for NSCLC. Approximately 23%-30% of NSCLC patients are synchronous BM at their initial diagnosis. Previous studies reported that the 3-year cumulative rate of BMs ranges from 29.4% to 60.3% in patients with mutated EGFR.

Currently, the clinical benefits of existing treatments for third-generation EGFR TKI-resistant NSCLC are limited and DZD6008 is expected to fill the unmet medical needs. DZD6008 effectively inhibits EGFR-mutated tumor growth in cell lines and in animal models. Previous clinical studies have validated the design concept of the molecule and suggest that DZD6008 demonstrates good safety and efficacy in NSCLC patients with brain metastases who had failed third-generation EGFR TKI therapy or multiple lines of pre-treatments.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on LinkedIn or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com

Source

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

0

CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company’s TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) in combination with pembrolizumab (KEYTRUDA®[1], MSD’s anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), was presented as an oral presentation by Professor Caicun Zhou from Shanghai East Hospital, Tongji University (Abstract #8506, Lung Cancer – Metastatic Non-Small Cell).


Sac-TMT is designed with a unique, bifunctional linker and differentiated belotecan-derivative payload. The linker is conjugated via cysteine, which maximizes payload delivery to tumor cells both through its irreversible connection with the high-affinity and targeting anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a moderately toxic novel topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4.


In the OptiTROP-Lung05 study, a total of 413 patients were randomized (1:1) to receive either sac-TMT in combination with pembrolizumab or pembrolizumab monotherapy.


As of the data cutoff date (September 29, 2025), with a median follow‑up of 10.5 months, the study demonstrated that:

  • Progression-free survival (PFS) showed statistically significant and clinically meaningful benefit in sac-TMT plus pembrolizumab compared with pembrolizumab alone. The median PFS assessed by blinded independent central review (BICR) was not reached (NR) vs 5.7 months (HR=0.35; 95% CI: 0.26-0.47; p<0.0001). The 12-month PFS rate was 62.4% vs 29.0%.


  • Consistent benefit across prespecified subgroups: In patients with PD‑L1 TPS ≥50% and TPS 1–49%, the PFS HRs were 0.47 (95% CI: 0.29–0.77) and 0.28 (95% CI: 0.19–0.41), respectively. In patients with non‑squamous and squamous NSCLC, the PFS HRs were 0.28 (95% CI: 0.18–0.43) and 0.44 (95% CI: 0.29–0.66), respectively.



  • Overall survival (OS) was not yet mature but showed a positive trend: median OS was NR vs 14.5 months (HR = 0.55; 95% CI: 0.36–0.85). The 12‑month OS rate was 80.4% vs 68.9%.
  • The combination group showed improvements over pembrolizumab monotherapy group in objective response rate (ORR) (70.2% vs 42.0%), deep response rate (49.0% vs 25.9%), and 12-month duration of response rate (77.7% vs 59.4%).


The incidence of grade ≥3 treatment-emergent adverse events (TEAEs) was higher in the combination group, primarily driven by the expected hematologic adverse events of sac-TMT. Incidence of discontinuation of pembrolizumab due to TEAEs was similar in both groups. No sac-TMT-related deaths occurred. Adverse events of special interest (AEOSIs) were consistent with the known safety profiles of each individual agent, and no new safety signals were identified.

The interim analysis results show that sac-TMT plus pembrolizumab significantly prolonged PFS and reduced the risk of disease progression or death compared with pembrolizumab alone, with consistent PFS benefits observed across all prespecified subgroups (including PD‑L1 expression levels and histological subtypes). A positive trend in OS was also observed. Furthermore, the overall safety profile of sac-TMT in combination with pembrolizumab was manageable, consistent with the established safety profiles of sac-TMT alone or pembrolizumab alone.

Notably, the findings of OptiTROP-Lung05 have been simultaneously published in The Lancet(Impact Factor=88.5), indicating that its clinical and academic value has received dual recognition from a leading international academic conference and an authoritative journal.


Professor Caicun Zhou, the national leading principal investigator from Shanghai East Hospital, Tongji University, said: “The positive results of the OptiTROP‑Lung05 study are encouraging. The study not only supports the application of sac‑TMT in an earlier-line setting for lung cancer, but also provides evidence of the ‘ADC+IO’ synergistic strategy being evaluated in the first-line setting for PD‑L1‑positive advanced NSCLC, potentially bringing a new option to a broad population of patients with lung cancer.”

[1] KEYTRUDA® (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About sac-TMT(佳泰莱®)

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and platinum-based chemotherapy; 3) epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the National Medical Products Administration (NMPA).

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

Source

Experts identify victims from one of history’s most ‘catastrophic’ Arctic disasters

0

NEWYou can now listen to Fox News articles!

Around 180 years after Sir John Franklin’s doomed expedition to find the Northwest Passage ended in disaster, researchers have identified four additional crew members through DNA analysis.

The new research, shedding light on one of history’s most infamous Arctic tragedies, was led by researchers at the University of Waterloo in Ontario, Canada

The identified remains include William Orren, Able Seaman; David Young, Boy 1st Class; John Bridgens, Subordinate Officers’ Steward; and Harry Peglar, Captain of the Foretop on HMS Terror.

PARK RANGERS UNEARTH 200-YEAR-OLD SHIPWRECK ON REMOTE ISLAND DUBBED ‘GRAVEYARD OF THE ATLANTIC’

Franklin, a British explorer, brought 129 officers and crew members aboard HMS Erebus and HMS Terror in 1845 in an attempt to chart the Northwest Passage.

The vessels became trapped in ice near King William Island in Nunavut in September 1846 — and Franklin died in 1847.

Stenton analyzing site of remains next to portrait or Franklin

Researchers have identified four more crew members from the doomed expedition. Study co-author Douglas Stenton is shown at left during the excavation of bones; at right is Sir John Franklin, who set out to find the Northwest Passage beginning in 1845. (University of Waterloo; iStock)

In April 1848, the surviving crew abandoned the vessels and tried escaping on foot and by dragging boats across the Arctic terrain, but no one survived.

“All 105 died trying to escape,” the University of Waterloo said in a May 6 statement. Its study was published in the Journal of Archaeological Science: Reports in May.

MYSTERY SOLVED? RESEARCHER CHALLENGES LONG-HELD THEORY OF WHAT SANK SHACKLETON’S ENDURANCE IN ANTARCTIC ICE

“Remains of expedition members have been found on King William Island and the Adelaide Peninsula since the mid-19th century,” the researchers said. 

University of Waterloo anthropologists did DNA analysis of skeletal remains recovered from Franklin expedition sites, finding that the samples matched DNA donated by living descendants.

Split image of Franklin vessels stuck in ice, Stenton working at Arctic site

The Franklin expedition set sail in 1845 with 129 men aboard HMS Erebus and HMS Terror before disaster struck in the Arctic. (API/Gamma-Rapho via Getty Images; University of Waterloo)

Study co-author Stephen Fratpietro of Lakehead University compared DNA from the remains with living descendants and found exact genetic matches in all four cases.

These new discoveries bring the total number of identified sailors of the Franklin expedition to six, as researchers previously identified John Gregory in 2021 and Captain James Fitzjames in 2024.

RARE 16TH-CENTURY SHIPWRECK FOUND AT RECORD DEPTH IN FRENCH WATERS: ‘REMARKABLE DISCOVERY’

The journey to find the Northwest Passage was “dangerous for many reasons,” study co-author Douglas Stenton told Fox News Digital.

“The main threats came from the harsh Arctic environment: extreme winter cold, a short sailing season that could force the crew to overwinter, ice capable of crushing a ship, strain on the men’s physical and mental health, and the constant risk of death from illness or injury working under these conditions,” he said.

The Franklin expedition was “the largest and arguably best-equipped Arctic expedition of its time.”

Stenton said the DNA analysis process yielded several surprises — including the identification of Captain James Fitzjames in 2024, whose remains showed evidence of cannibalism.

“Captain Fitzjames is not the only member of the expedition whose body suffered that fate, but he is the only one who has been identified,” he said.

CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER

Researchers were also amazed to find that five of the six identified sailors were discovered near two boats less than 1.25 miles apart along Erebus Bay, he said.

Researchers said Peglar’s identification was surprising because the body was dressed as a steward, leading some experts to believe the remains belonged to another man.

Split image of researchers working at Arctic site, sketch of deceased sailor

Researchers identified David Young, Boy 1st Class aboard HMS Erebus, through DNA analysis of remains discovered at Erebus Bay. (University of Waterloo; Diana Trepkov, Investigative Forensic Artist)

Stenton believes Peglar was dressed as a steward “because he had been demoted to that position due to misconduct.”

Stenton added, “A petty officer is an experienced sailor with important responsibilities. … Because of the clothing, many researchers assumed that Peglar had died and that the body was not his, but [rather] that of a friend who was a steward and who was carrying Peglar’s papers home to his family.”

CLICK HERE FOR MORE LIFESTYLE STORIES

However, he said, “167 years after the discovery of the body, our research has conclusively disproven that theory.”

Extracting usable DNA from the remains was challenging because genetic material naturally deteriorates over time, even in Arctic conditions, Stenton said.

Depiction of Franklin sailors sitting in ice

Historians and researchers continue uncovering new details about the doomed Franklin expedition nearly two centuries after the disaster unfolded. (PHAS/Universal Images Group via Getty Images)

To improve their chances, scientists primarily analyzed teeth. The hard enamel can better preserve DNA after years of exposure to weather and the elements.

Stenton added that the Northwest Passage was so sought-after because it was viewed as a potential trade route between the Atlantic and Pacific oceans, offering faster access to markets in Asia.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The Franklin expedition was also “the largest and arguably best-equipped Arctic expedition of its time,” he said, meaning that its success promised major prestige and pride for Britain.

Next steps include working with genealogists and descendants to identify more crew members, as well as potentially collecting additional archaeological DNA samples in the future.

Image of Franklin expedition vessels sailing in water

The Franklin expedition set sail in 1845 with 129 officers and crew members aboard HMS Erebus and HMS Terror in search of the Northwest Passage. (The Print Collector/Heritage Images via Getty Images)

Stenton said DNA research is helping scientists develop “a better understanding of the catastrophic loss of life,” while also providing some closure for families.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“Just as importantly, the research both depends on and invites the participation of descendants of the men who never returned home, which feels especially fitting,” he said.

Source

Travelers to Europe may be leaving money on the table. Here’s why

0

Shoppers enter and exit a Dior luxury boutique in Venice, Italy, on Nov. 16, 2025.

Michael Nguyen/NurPhoto via Getty Images

Travelers to Europe may be leaving money on the table when they buy goods there.

I learned this during a recent trip to Italy. My girlfriend, who bought a pair of shoes in Venice, was able to claim a refund on the value-added tax she paid on the purchase.

She ultimately got back 17 euros (US$20) on a total purchase of 155 euros (US$181).

Refunds of value-added tax, known as VAT, can be worth a “chunk of money” for U.S. travelers to Europe, depending on what they buy and in which country they purchase the item, said Sofia Markovich, a travel advisor and founder of Sofia’s Travel.

Late bookings and different destinations: travel impact of Iran war

Getting a few extra dollars back after a European vacation may help somewhat defray the higher cost of airfare resulting from the Iran war, and a euro-U.S. dollar exchange rate that has become less favorable in recent years.

However, we would have missed out had the Italian shopkeeper not asked whether we wanted the paperwork necessary to claim the refund later, which we did with relative ease at an airport kiosk in Rome.

Many times, stores don’t flag the option for customers, experts said.

“You have to remember to get [the paperwork] in the shop, because not every shop will remind you of it,” Markovich said. “You personally have to be proactive about it.”

For some, the additional hassle — which generally includes an extra stop at the airport — may not be worth it for lower-value items, said Sally French, a travel expert at NerdWallet.

“It’s a nice-to-have, but I’m not getting to the airport early to save $10,” she said.

‘Definitely worth it’ for luxury goods

People shopping in the city center of Bonn, Germany, on April 25, 2026.

Ying Tang/NurPhoto via Getty Images

Value-added taxes are a tax on domestic consumption, like retail sales taxes charged by U.S. state and local governments.

VATs are the most common type of consumption tax in the world, used by more than 170 countries worldwide.

European nations levy a range of VAT rates, which can also vary by product.

Standard VAT rates range from 8.1% in Switzerland to 27% in Hungary, according to the Tax Foundation.

Spain, for example, has a standard VAT rate of 21% but carries a lower rate for certain items, like 10% for sunglasses and 4% for books and magazines, according to Global Blue, a payments company that helps facilitate VAT refunds.

However, not all purchases qualify for a refund, experts said.

Read more CNBC personal finance coverage

For one, refunds are generally only meant for merchandise, and not for certain categories like hotels and meals, experts said.

Many countries also impose a minimum value on purchases to be eligible.

“Typically, you must ring up the minimum at a single retailer — you can’t add up purchases from various shops to reach the required amount — so if you’re doing a lot of shopping, you’ll benefit from finding one spot where you can buy big,” Rick Steves, a travel expert who has authored a series of guide books, wrote in an article about VAT refunds.

For example, countries like Greece and the Netherlands require that travelers spend at least 50 euros (US$58) at a retailer in order to claim a refund, according to Rick Steves’ Europe, a travel and tour company. In Italy, the minimum is 75 euros (US$88); France’s is 100 euros (US$117). In Switzerland, the minimum is 300 Swiss francs (US$384). Spain, on the other hand, doesn’t have a minimum.

Claiming the refund “is definitely worth it” for travelers buying luxury goods, like high-end fashion or jewelry, Markovich said.

“It can be in the hundreds of dollars back, or even thousands, depending on what you’re buying,” Markovich said. “I know people who go to Europe just to shop.”

Travelers also aren’t supposed to use their goods before leaving Europe, Steves wrote.

“If you show up at customs wearing your new Dutch clogs, officials may deny you a refund,” he wrote.

The refund process

Travelers at a refund shop at Adolfo Suárez Madrid-Barajas Airport in Spain, preparing to claim VAT refunds before their international flights.

Xavi Lopez/SOPA Images/LightRocket via Getty Images

There’s typically a multistep process to claim VAT refunds, experts said.

Participating merchants generally must fill out a refund document, and will need the traveler’s passport (or, sometimes, a photo of the passport) to do so, Steves wrote.

In most cases, travelers will need to then process those documents at their final stop in Europe, most likely the airport, Steves wrote.

“At some airports, you’ll have to go to a customs office to get your documents stamped and then to a separate VAT refund service, such as Global Blue or Planet, to process the refund,” Steves wrote. “At other airports, a single VAT desk handles the whole thing.”

Europe is still a hot destination for U.S. tourists, says Mastercard's Michelle Meyer

Refund services typically charge a fee — generally around 4% or so — so travelers likely won’t receive the VAT’s full value, Steves wrote.

Travelers should remember to process the documents at their last stop in the European Union, Steves said.

“So, if you buy sweaters in Denmark, pants in France, and shoes in Italy, and you’re flying home from Greece, get your documents stamped at the airport in Athens,” he wrote, adding, “And don’t forget: Switzerland, Norway, and Turkey are not in the EU, so if you shop in one of those countries, get your documents stamped before you cross the border.”

Tax free refunds line at Josep Tarradellas Barcelona-El Prat Airport in Spain.

Jeff Greenberg | Universal Images Group | Getty Images

Customs offices are sometimes located before airport security, and agents may ask to see travelers’ unused goods, he wrote.

The whole process was simple for us: It took about five minutes from start to finish at one digital kiosk at the airport in Rome, which we accessed just before the security checkpoint. Others will need to budget more time if they want to claim a refund, experts said.

In some countries, “there is a line, and then you have to budget extra time when you go to the airport to wait in that line,” said NerdWallet’s French.

“I’d question whether it’s worth spending time in the airport for,” she said. “It makes sense if you’re buying a $5,000 designer bag. But time is money, and it’s OK to skip on saving a couple dollars here and there for the time and work involved.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

Source

Unlikely hero Michael Sellwood produces match-saving mark as Dogs hold on against Pies

0

The Western Bulldogs have held off a spirited Collingwood to hang on for a four-point victory in a thriller on Saturday night.

The Dogs led for nearly the entire night, but the Pies surged home late to nearly steal a famous win, only for unlikely hero Michael Sellwood to produce a stunning mark in the final minute.

WATCH THE VIDEO ABOVE: Michael Sellwood’s match-saving mark

Know the news with the 7NEWS app: Download today Arrow

Will Lewis looked like being the hero when his goal put the Dogs up by 10 points with a couple minutes remaining, but there was still time for one final twist.

Tim Membrey cut the deficit to four with a quick snap to set up a thrilling finale.

The Pies had one final chance, but were thwarted by Sellwood, who went back with the flight and took a brilliant game-saving mark.

Sellwood hauled in a courageous match-saving mark.
Sellwood hauled in a courageous match-saving mark. Credit: Fox Footy

From that point, the Dogs controlled the ball to seal the win and improve their win-loss record to 7-5.

Arriving at the club via last year’s mid-season rookie draft, Sellwood was playing just the 12th game of his career.

“I just saw the ball and I was like ‘I really gotta go here and if I go, I gotta mark it’,” he told Fox Footy after the match.

“Luckily it stuck because (Pat) Lipinski probably would have got the ball. Glad it stuck and the rest is history.”

Captain Marcus Bontempelli wasn’t surprised the inexperienced teammate produced the clutch moment.

“It’s not a surprise. He’s become one of the more reliable players in our team with regards to his contest, his physicality,” he said.

“You can tell he has the desperation, getting drafted later (in life), not giving up on his opportunity and you can tell every week he is just relishing it.

“Stuff like that … in his first contest at his first training session he almost killed Liam Jones going back with the flight, and right then and there you knew what he was about.

“It was exactly like that play, head in the hole, no concern for his wellbeing or his body.”

The commentators were in awe of the incredible mark.

“What courage that takes to leave your man. If you don’t mark it, your man is likely sitting at ground level and will have a chence to win the game,” North Melbourne great David King said.

Matt Kennedy (29 touches), Ed Richards (24) and Ryley Sanders (28) shone for the Dogs, while Marcus Bontempelli (22 disposals, nine clearances) starred for three quarters before he was blunted by Angus Anderson late.

First-year key forward Lewis kicked three crucial goals, including the Dogs’ last of the match, while Richards, English and Lachlan McNeill kicked two each.

The result lifted the Bulldogs (7-5) to seventh and left Collingwood (5-6-1) in danger of slipping out of the top 10 by the end of the round.

The Magpies’ loss came despite the efforts of explosive midfielder Jordan De Goey, who was best afield with 30 disposals, 19 score involvements and one goal.

Nick Daicos (37 touches) and veteran Scott Pendlebury (33) — one week after breaking the all-time AFL/VFL games record — were also strong contributors for the Pies.

Tim Membrey kicked three goals, with Lachie Schultz and Anderson adding two each.

The Bulldogs had early ascendancy and kicked four of the first five goals, with Arthur Jones dangerous at ground level in attack.

They led by seven points at quarter-time and extended the margin to 17 by the main break.

It could, perhaps should, have been greater as the Dogs dominated the clearance (25-14) and inside-50 (32-18) counts to that point.

They were also denied a free kick seconds before the siren when Bontempelli was taken out by Brayden Maynard when running on to a loose ball in front of goal.

Collingwood slashed the margin to one straight kick midway through the third term, but the Dogs responded with three majors in six minutes to keep them at bay, leading by 24 points not long before three-quarter time.

The Pies lifted again, kicking the next three goals, and had a chance to tie the scores early in the final term when Schultz pushed a set shot wide.

A rollicking last quarter went down to the wire.

Lewis pounced to give the Dogs a 10-point lead, before Membrey gave Collingwood a sniff with his third goal with 85 seconds left on the clock.

But Sellwood was on hand to save the day for the Dogs with his courageous mark.

— with AAP

Source

The 7th China-CEEC Local Leaders’ Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week Successfully Held

0

JINAN, China, May 30, 2026 /PRNewswire/ — From May 25 to 29, 2026, the 7th China–CEEC Local Leaders’ Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week, hosted by Shandong Provincial People’s Government, the Secretariat of Cooperation between China and Central and Eastern European Countries, and China-CEEC Association of Provincial Governors, was successfully held. More than 600 Chinese and international guests from 44 countries and 15 provinces, autonomous regions and municipalities across China gathered in Shandong to advance cooperation, share opportunities and shape the future together.

The 7th China–CEEC Local Leaders’ Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week
The 7th China–CEEC Local Leaders’ Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week

Under the theme “Shaping the Future Together,” the event featured 23 activities, including the Opening Ceremony, China–CEEC Local Leaders’ Dialogue, Governors’ Dialogue, High-Quality Development Promotion Session, and Business Matchmaking. The event further expanded all-round and targeted exchanges and cooperation between Shandong and CEECs as well as international friendship cities, promoting higher-level of mutually beneficial cooperation and coordinated development.

Several distinguished guests attended the opening ceremony and delivered remarks, including Ivan Stoilkovikj, Deputy Prime Minister and Minister for Inter-Community Relations of North Macedonia, Adrijana Mesarović, Deputy Prime Minister and Minister of Economy of Serbia, Marinko Čavara, Deputy Speaker of the House of Representatives of the Parliamentary Assembly of Bosnia and Herzegovina, and Mirsad Nurković, Vice-President of the Parliament of Montenegro. Activities such as friends talk and outcome release were also held, showcasing the achievements and opportunities of China–CEEC local cooperation as well as collaborations between Shandong and its international friendship cities, further enriching concrete outcomes and enhancing Shandong’s level of opening-up.

Klodiana Spahiu, Deputy Speaker of the Parliament of Albania, also attended related events.

The event demonstrated distinctive features of high-level engagement, diversity, practicality and coordinated development, playing an important role in deepening exchanges, expanding cooperation channels, empowering collaboration and achieving mutual benefit. Through the event, Shandong established friendly cooperative relations with Minsk Region of Belarus, the Ionian Islands Region of Greece, Maritime Region of Togo, and Jizzakh Region of Uzbekistan. Shandong’s international friendship network has now expanded to 93 pairs of friendship provinces and states, and 681 pairs of friendship cities across 109 countries. A series of celebration events were also held to mark Shandong’s friendship relations with South Australia and Connecticut, while projects such as the China–Greece Joint Laboratory on Smart Green Agriculture were launched.

Source